Madrigal Pharmaceuticals reports Q2 results tomorrow with the most striking pre-earnings positioning shift of the season: short sellers have cut their exposure nearly in half over 30 days, while two fresh analyst actions landed this week ahead of the print.
The short-side story has changed materially since mid-June. Short interest peaked near 3.8 million shares in late June and has fallen to roughly 1.95 million — 8.6% of float, down 42% in one week alone. That collapse came in a single session around July 23, when reported shares short dropped from 3.3 million to under 2 million overnight. Borrow conditions reflect the unwind: availability is 1,395%, meaning the lending pool has more than 13 shares available for every one currently borrowed. Cost to borrow has crept up 30% on the week to 0.42% but remains negligibly low in absolute terms. There is no squeeze pressure here — shorts have retreated, not been forced out.
Options positioning adds a layer of caution that the short-interest data does not. The put/call ratio is running at 0.45, about 1.7 standard deviations above its 20-day average of 0.42 — elevated relative to recent norms, though still well below the 52-week high of 0.76. The short score has also dropped sharply, falling from 64.3 on July 15 to 56.6 now, confirming the reduced short-side conviction. Overall, the lending market looks loose and the short thesis has largely been abandoned, but options traders are quietly adding more downside protection than usual into tomorrow's number.
The Street arrived into earnings week with fresh upgrades in hand. Wells Fargo initiated coverage Monday with an Overweight rating and a $685 target — the first new voice on the stock this week. Canaccord Genuity raised its target to $587 from $578 the same day, maintaining Buy. The consensus mean target is $681, implying roughly 26% upside from Tuesday's close of $538.80. The analyst recommendation differential factor ranks in the 98th percentile of the universe — a rare level of bullish alignment. Bank of America holds the lone cautious position, sitting at Neutral with a $542 target set in June, barely above current levels. Bulls cite Rezdiffra's commercial momentum in NASH and the validated GalNAc pipeline; bears flag competitive pressure and ongoing capital consumption. The PE has compressed sharply over 30 days — from roughly 192x to 125x — as earnings growth has caught up with valuation, though the stock still trades at 17x book.
One ownership detail is worth noting. CEO Bill Sibold sold approximately 2,500 shares across multiple transactions on July 20, collecting around $813,000 in aggregate at prices around $543-$555. The sales carry a trade significance score of 1 — the lowest possible — consistent with a routine plan sale rather than a discretionary move. The 90-day net insider position is actually positive at roughly 10,000 shares, so the directional signal from insiders as a whole remains constructive.
The last two earnings prints produced positive reactions: the stock rose 6.4% in a single day after the May result and added another 3.3% over the following week. The June event was more muted, with a 0.9% one-day move. Tomorrow's print is therefore less about whether Rezdiffra is growing and more about whether the commercial ramp is tracking to the pace the newly initiated and recently raised targets require.
See the live data behind this article on ORTEX.
Open MDGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
